Peptide and Heparin Market: Vendors of Peptide Therapeutics are Outsourcing Manufacturing Processes to Developing Countries
According to Fact.MR, the global peptide and heparin market is projected to reflect a high single-digit CAGR throughout the forecast period (2017-2026). The market is estimated to reach nearly US$ 35,000 Mn revenues by 2026-end.
A major component in the innate immune system, host defense peptides play an instrumental role in the defense against surmounting microbes. Such peptides have been providing not only direct broad-spectrum antimicrobial effects, but also an array of additional functionalities, encompassing immune modulating and anti-inflammatory effects along with effects on chemotaxis and angiogenesis. Meanwhile, heparin has becoming popular as an anti-inflammatory and antitumor agent, substantiated by new research finding among healthcare professionals.
The quashing of bovine heparin by the FDA was majorly attributed to the concern with respect to adulteration. Having said that, on the back of acute shortage of procine heparin, FDA has started to encourage bovine heparin manufacturers to reintroduce their product, which in turn has resulted in the surge of amount of crude heparin.
Get Free Sample Report Here:
https://www.factmr.com/connectus/sample?flag=S&rep_id=378
There has been significant use of heparin before surgeries, in the course of dialysis or blood transfusion and when blood is collated as a sample, which signifies the influence of heparin in curbing the risk of blood clotting.
New oral anticoagulants being efficacious and safe is witnessing a rising demand in Asia-Pacific excluding Japan (APEJ). Against the backdrop of side effect with respect to heparin products—complications of bleeding and thrombocytopenia—the adoption of oral anticoagulants has expanded. Nevertheless, development in peptides synthesis technology coupled with soaring demand for peptides therapies in APEJ is anticipated to fuel the growth in the region.
Peptides and Heparin Market: Overview
The report provides a robust analysis on the market for peptides and heparin for the assessment period 2018-2026. The report peruses into the dynamics surrounding the peptides and heparin which significantly impact the growth of the market.
Furthermore, the report discerns the segregation of the market which is anticipated to provide readers with an actionable insights which will aid them in taking proper decision based on segments historical and future growth estimates.
The report focuses on cost structure and supply chain to provide a comprehensive view of the peptides and heparin market. The report also includes disease epidemiology and technology roadmap along with product lifecycle. Further, PESTLE analysis gives overall picture of the peptides and heparin market. The report provides a coherent assessment through average pricing analysis. The report also includes regional and country-wise assessment.
Browse Full Report with ToC Here:
https://www.factmr.com/report/378/peptides-heparin-market
A qualitative and quantitative information has been obtained for the forecast and assessment on the peptides and heparin market. The research sources include primary and secondary sources which have been further examined by in-house panel of experts. The growth of end use industries in the historical and forecast period have been estimated to aid the readers with their business investment decisions. The market size of the peptides and heparin is the result of revenue comparison, market share comparison and Y-o-Y growth comparison on the geography.
Drug Developers Shifting Back to Peptides owing to Mounting Challenges regarding Small Molecules
While the pharmaceutical sector discerned small molecules as the medicinal agents, therapeutic peptides were considered to be niche products. However, with mounting challenges regarding small molecules, drug developers are shifting their concentration back to small amino acid chains. Although peptides have been deemed ineffective for developing drugs, modern peptide drug designs and formulations have been developed for circumventing their weaknesses.
Peptides and Heparin Market: Competitive Landscape
Leading market players being instrumental for the growth of the peptides and heparin market are profiled and assessed on the basis of company overview, financial overview, product offering, recent development, key differentiators and strategies. The report also includes SWOT analysis to provide a holistic picture of the competitive scenario of the peptides and heparin market. A deep dive analysis of the major market players becomes indispensable as it will succor readers to make proper decision to enlarge their business and can comprehend strategic moves made by prominent players in the peptides and heparin market.
The global market for peptide and heparin is high fragmented and competitive owing to the presence of a large number of international and regional vendors. These vendors are continuously focusing on the development of generic formulations related to blood coagulation and several other novel therapeutic areas. Companies having the capability of manufacturing drugs for effective treatment of coagulation disorders, along with high efficacy and safety profiles are likely to gain maximum market shares in the foreseeable future. Key market participants identified by the report include Baxter, Celsus, Biofer S.p.A,, Hemmo Pharma, AmbioPharm, Inc., Wockhardt Ltd., Sun Pharmaceutical Industries Ltd., Bachem, Abbott Laboratories, Pfizer Inc., Aspen, Leo Pharma, Teva, Takeda, Sanofi, Novo Nordisk, and Eli Lilly.
A major component in the innate immune system, host defense peptides play an instrumental role in the defense against surmounting microbes. Such peptides have been providing not only direct broad-spectrum antimicrobial effects, but also an array of additional functionalities, encompassing immune modulating and anti-inflammatory effects along with effects on chemotaxis and angiogenesis. Meanwhile, heparin has becoming popular as an anti-inflammatory and antitumor agent, substantiated by new research finding among healthcare professionals.
The quashing of bovine heparin by the FDA was majorly attributed to the concern with respect to adulteration. Having said that, on the back of acute shortage of procine heparin, FDA has started to encourage bovine heparin manufacturers to reintroduce their product, which in turn has resulted in the surge of amount of crude heparin.
Get Free Sample Report Here:
https://www.factmr.com/connectus/sample?flag=S&rep_id=378
There has been significant use of heparin before surgeries, in the course of dialysis or blood transfusion and when blood is collated as a sample, which signifies the influence of heparin in curbing the risk of blood clotting.
New oral anticoagulants being efficacious and safe is witnessing a rising demand in Asia-Pacific excluding Japan (APEJ). Against the backdrop of side effect with respect to heparin products—complications of bleeding and thrombocytopenia—the adoption of oral anticoagulants has expanded. Nevertheless, development in peptides synthesis technology coupled with soaring demand for peptides therapies in APEJ is anticipated to fuel the growth in the region.
Peptides and Heparin Market: Overview
The report provides a robust analysis on the market for peptides and heparin for the assessment period 2018-2026. The report peruses into the dynamics surrounding the peptides and heparin which significantly impact the growth of the market.
Furthermore, the report discerns the segregation of the market which is anticipated to provide readers with an actionable insights which will aid them in taking proper decision based on segments historical and future growth estimates.
The report focuses on cost structure and supply chain to provide a comprehensive view of the peptides and heparin market. The report also includes disease epidemiology and technology roadmap along with product lifecycle. Further, PESTLE analysis gives overall picture of the peptides and heparin market. The report provides a coherent assessment through average pricing analysis. The report also includes regional and country-wise assessment.
Browse Full Report with ToC Here:
https://www.factmr.com/report/378/peptides-heparin-market
A qualitative and quantitative information has been obtained for the forecast and assessment on the peptides and heparin market. The research sources include primary and secondary sources which have been further examined by in-house panel of experts. The growth of end use industries in the historical and forecast period have been estimated to aid the readers with their business investment decisions. The market size of the peptides and heparin is the result of revenue comparison, market share comparison and Y-o-Y growth comparison on the geography.
Drug Developers Shifting Back to Peptides owing to Mounting Challenges regarding Small Molecules
While the pharmaceutical sector discerned small molecules as the medicinal agents, therapeutic peptides were considered to be niche products. However, with mounting challenges regarding small molecules, drug developers are shifting their concentration back to small amino acid chains. Although peptides have been deemed ineffective for developing drugs, modern peptide drug designs and formulations have been developed for circumventing their weaknesses.
Peptides and Heparin Market: Competitive Landscape
Leading market players being instrumental for the growth of the peptides and heparin market are profiled and assessed on the basis of company overview, financial overview, product offering, recent development, key differentiators and strategies. The report also includes SWOT analysis to provide a holistic picture of the competitive scenario of the peptides and heparin market. A deep dive analysis of the major market players becomes indispensable as it will succor readers to make proper decision to enlarge their business and can comprehend strategic moves made by prominent players in the peptides and heparin market.
The global market for peptide and heparin is high fragmented and competitive owing to the presence of a large number of international and regional vendors. These vendors are continuously focusing on the development of generic formulations related to blood coagulation and several other novel therapeutic areas. Companies having the capability of manufacturing drugs for effective treatment of coagulation disorders, along with high efficacy and safety profiles are likely to gain maximum market shares in the foreseeable future. Key market participants identified by the report include Baxter, Celsus, Biofer S.p.A,, Hemmo Pharma, AmbioPharm, Inc., Wockhardt Ltd., Sun Pharmaceutical Industries Ltd., Bachem, Abbott Laboratories, Pfizer Inc., Aspen, Leo Pharma, Teva, Takeda, Sanofi, Novo Nordisk, and Eli Lilly.
Comments
Post a Comment